Excitotoxic and excitoprotective mechanisms

Laboratory of Neurosciences, National Institute on Aging Gerontology Research Center, 5600 Nathan Shock Drive, 21224 Baltimore, MD; Department of Neuroscience, Johns Hopkins University School of Medicine, 725 North Wolfe Street, 21205 Baltimore, MD
NeuroMolecular Medicine (Impact Factor: 4.49). 3(2):65-94. DOI: 10.1385/NMM:3:2:65

ABSTRACT Activation of glutamate receptors can trigger the death of neurons and some types of glial cells, particularly when the cells
are coincidentally subjected to adverse conditions such as reduced levels of oxygen or glucose, increased levels of oxidative
stress, exposure to toxins or other pathogenic agents, or a disease-causing genetic mutation. Such excitotoxic cell death
involves excessive calcium influx and release from internal organelles, oxyradical production, and engagement of programmed
cell death (apoptosis) cascades. Apoptotic proteins such as p53, Bax, and Par-4 induce mitochondrial membrane permeability
changes resulting in the release of cytochrome c and the activation of proteases, such as caspase-3. Events occurring at several
subcellular sites, including the plasma membrane, endoplasmic reticulum, mitochondria and nucleus play important roles in
excitotoxicity. Excitotoxic cascades are initiated in postsynaptic dendrites and may either cause local degeneration or plasticity
of those synapses, or may propagate the signals to the cell body resulting in cell death. Cells possess an array of anti-excitotoxic
mechanisms including neurotrophic signaling pathways, intrinsic stress-response pathways, and survival proteins such as protein
chaperones, calcium-binding proteins, and inhibitor of apoptosis proteins. Considerable evidence supports roles for excitotoxicity
in acute disorders such as epileptic seizures, stroke and traumatic brain and spinal cord injury, as well as in chronic age-related
disorders such as Alzheimer’s, Parkinson’s, and Huntington’s disease and amyotrophic lateral sclerosis. A better understanding
of the excitotoxic process is not only leading to the development of novel therapeutic approaches for neurodegenerative disorders,
but also to unexpected insight into mechanisms of synaptic plasticity.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Resolution enhancement for glutamate (Glu), glutamine (Gln) and glutathione (GSH) in the human brain by TE-optimized point-resolved spectroscopy (PRESS) at 7 T is reported. Sub-TE dependences of the multiplets of Glu, Gln, GSH, γ-aminobutyric acid (GABA) and N-acetylaspartate (NAA) at 2.2-2.6 ppm were investigated with density matrix simulations, incorporating three-dimensional volume localization. The numerical simulations indicated that the C4-proton multiplets can be completely separated with (TE(1), TE(2)) = (37, 63) ms, as a result of a narrowing of the multiplets and suppression of the NAA 2.5 ppm signal. Phantom experiments reproduced the signal yield and lineshape from simulations within experimental errors. In vivo tests of optimized PRESS were conducted on the prefrontal cortex of six healthy volunteers. In spectral fitting by LCModel, Cramér-Rao lower bounds (CRLBs) of Glu, Gln and GSH were 2 ± 1, 5 ± 1 and 6 ± 2 (mean ± SD), respectively. To evaluate the performance of the optimized PRESS method under identical experimental conditions, stimulated-echo spectra were acquired with (TE, TM) = (14, 37) and (74, 68) ms. The CRLB of Glu was similar between PRESS and short-TE stimulated-echo acquisition mode (STEAM), but the CRLBs of Gln and GSH were lower in PRESS than in both STEAM acquisitions.
    NMR in Biomedicine 11/2010; 23(9):1044-52. · 3.45 Impact Factor
  • Journal of Neuroscience Research 10/2010; · 2.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Positive allosteric modulators (PAMs) of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are a diverse class of compounds that increase fast excitatory transmission in the brain. AMPA PAMs have been shown to facilitate long-term potentiation, strengthen communication between various cortical and subcortical regions, and some of these compounds increase the production and release of brain-derived neurotrophic factor (BDNF) in an activity-dependent manner. Through these mechanisms, AMPA PAMs have shown promise as broad spectrum pharmacotherapeutics in preclinical and clinical studies for various neurodegenerative and psychiatric disorders. In recent years, a small collection of preclinical animal studies has also shown that AMPA PAMs may have potential as pharmacotherapeutic adjuncts to extinction-based or cue-exposure therapies for the treatment of drug addiction. The present paper will review this preclinical literature, discuss novel data collected in our laboratory, and recommend future research directions for the possible development of AMPA PAMs as anti-addiction medications.
    Pharmaceuticals 01/2013; 7(1):29-45.